COVID-19 frequency and clinical course in children with asthma

Table 2 Evaluation of therapeutic features in different groups of asthma patients

	Others1 (n = 169)	Vaccinated patients (n = 57)	Atopic patients (n = 64)	P value	ES
Preventive/prophylactic asthma medication usage	31/164 (18.9)	9/57 (16.1)	16/62 (25.8)	0.372	0.084
Salbutamol usage	34/164 (20.7)	11/57 (19.6)	20/63 (31.7)	0.169	0.112
Prednol usage	2/164 (1.2)	1/57 (1.8)	0/64 (0)	0.619	0.059
Emergency service admission	27/164 (16.5)	8/57 (14)	14/64 (21.9)	0.485	0.071
Hospitalization	7/164 (4.3)	3/57 (5.3)	4/64 (6.3)	0.866	0.038

¹This column includes asthma patients who are neither atopic nor vaccinated.

Statistics were shown as n/total n (%). ES: Effect size (Cramer v coefficient).